Generali Investments CEE investicni spolecnost a.s. Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Generali Investments CEE investicni spolecnost a.s. lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 48.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,830 shares of the company's stock after selling 17,000 shares during the period. Generali Investments CEE investicni spolecnost a.s.'s holdings in Johnson & Johnson were worth $2,957,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $29,000. Conquis Financial LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $33,000. Bernard Wealth Management Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $38,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on JNJ. Morgan Stanley increased their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. Raymond James Financial reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Finally, Bank of America reduced their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Trading Down 0.5%

Shares of NYSE JNJ traded down $0.78 during mid-day trading on Monday, reaching $155.23. 6,263,851 shares of the company's stock were exchanged, compared to its average volume of 8,052,571. The firm has a market capitalization of $373.49 billion, a price-to-earnings ratio of 17.27, a PEG ratio of 2.36 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company's 50-day moving average is $153.68 and its 200-day moving average is $154.17.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.35%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.